Stock CRVS CORVUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Market Closed - Nasdaq
Other stock markets
 01:30:00 29/06/2024 am IST 		5-day change 1st Jan Change
1.82 USD -2.67% Intraday chart for Corvus Pharmaceuticals, Inc. +2.25% +3.41%
07/05 Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing MT
07/05 Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
AQ
Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing
MT
Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating
MT
Transcript : Corvus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 06, 2024
Corvus: Q1 Earnings Snapshot
AQ
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
AQ
Corvus Pharmaceuticals, Inc. Provides Business Update
CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
AQ
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
AQ
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings
MT
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
AQ
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
CI
Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating
MT
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2
MT
Transcript : Corvus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024
Corvus: Q4 Earnings Snapshot
AQ
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRVS Stock
  4. News Corvus Pharmaceuticals, Inc.